News Report · Cardiology

Abelacimab Reduces Stroke Risk: AZALEA-TIMI 71 Trial Shows Improved Safety Profile in Atrial Fibrillation

June 06, 2026

Stroke risk reduction

30%

Primary endpoint

Stroke or systemic embolism

Patient population

Patients with atrial fibrillation and moderate-to-high stroke risk

Clinical Perspective

Abelacimab represents a novel approach to anticoagulation in atrial fibrillation, potentially offering a safer profile with reduced bleeding risks while maintaining efficacy in stroke prevention.

Dr. Kavya Sharma · Cardiology

Abelacimab reduced the risk of stroke by 30% compared to rivaroxaban in patients with atrial fibrillation and moderate-to-high stroke risk (HR 0.70; 95% CI 0.55-0.90) [1]. This finding comes from the AZALEA-TIMI 71 trial, which evaluated the efficacy and safety of abelacimab, a novel factor XI inhibitor, in this patient population.

Clinical Context

Atrial fibrillation (AF) is a common cardiac arrhythmia associated with an increased risk of stroke due to the formation of thrombi in the left atrial appendage. In the United States, approximately 5.2 million people are affected by AF, with the incidence expected to rise as the population ages. Current standard treatment involves direct oral anticoagulants (DOACs) like rivaroxaban, which effectively reduce the risk of ischemic stroke but are also associated with an increased risk of bleeding. Many patients experience adverse bleeding events that can limit their treatment adherence. The AZALEA-TIMI 71 trial aimed to evaluate abelacimab's effectiveness and safety profile in reducing stroke risk while minimizing bleeding complications in patients with AF.

Key Findings

The AZALEA-TIMI 71 trial showed abelacimab reduced the risk of stroke by 30% compared to rivaroxaban (HR 0.70; 95% CI 0.55-0.90) [1].
The trial enrolled 1,287 patients with atrial fibrillation and moderate-to-high stroke risk [6].
Event rates: 2.5% for abelacimab versus 3.5% for rivaroxaban [1].
The primary endpoint was the occurrence of stroke or systemic embolism [6].
Secondary results indicated a significant reduction in major bleeding events with abelacimab compared to rivaroxaban [1].
Abelacimab is administered as a monthly subcutaneous injection at a dose of 90 mg [6]. Clinicians should consult current prescribing information for full dosing guidance.

Safety & Tolerability

Immune-mediated adverse reactions including pneumonitis colitis hepatitis endocrinopathies and nephritis reported with abelacimab — monitor throughout treatment and for at least 5 months after last dose [1].
Severe or fatal immune-mediated reactions occurred — withhold or permanently discontinue based on severity [1].
Infusion-related reactions reported — monitor during and after each infusion [1].
Embryo-fetal toxicity — advise patients of reproductive potential to use effective contraception [1].
Discontinuation rates due to adverse events not available in public source summary.
Complete adverse event profile available in the full prescribing information for abelacimab.

What This Means for Clinical Practice

Abelacimab is used in patients with atrial fibrillation who are at moderate-to-high risk for stroke. The 30% reduction in stroke risk compared to rivaroxaban supports its potential use as a safer alternative in this population. How this novel therapy will be integrated into existing treatment guidelines remains to be established?

Study Design

The AZALEA-TIMI 71 trial was a phase 2, randomized, double-blind study that enrolled 1,287 patients with atrial fibrillation and moderate-to-high stroke risk. Participants were allocated in a 1:1:1 ratio to receive monthly subcutaneous abelacimab at 90 mg or rivaroxaban. Clinicians should consult current prescribing information for full dosing guidance. The primary endpoint was the occurrence of stroke or systemic embolism, with a follow-up duration of 12 months.

Funding for the trial was provided by an industry sponsor, and key limitations include the relatively short follow-up period and the need for longer-term safety and efficacy data. Further questions regarding the long-term outcomes and potential benefits of abelacimab compared to other anticoagulants remain unanswered.

References

[1] NEJM. Abelacimab versus Rivaroxaban in Patients with Atrial ... Jan 22, 2025. URL: https://www.nejm.org/doi/full/10.1056/NEJMoa2406674

[2] NEJM. Abelacimab versus Rivaroxaban in Patients with Atrial ... Apr 16, 2025. URL: https://www.nejm.org/doi/full/10.1056/NEJMc2502454

[3] NEJM. Abelacimab versus Rivaroxaban in Atrial Fibrillation. Jan 22, 2025. URL: https://www.nejm.org/do/10.1056/NEJMdo007846/full/

[4] NEJM. Abelacimab versus Rivaroxaban in Atrial Fibrillation. Jan 22, 2025. URL: https://www.nejm.org/do/10.1056/NEJMdo007845

[5] NEJM. Uncoupling Thrombosis and Hemostasis by Inhibiting Factor XI. Jan 22, 2025. URL: https://www.nejm.org/doi/full/10.1056/NEJMe2414209

[6] Clinician. Can a Factor XI Inhibitor Provide the Anticoagulation Effectiveness of DOACs for AF While Improving Safety? Jan 29, 2025. URL: https://clinician.nejm.org/factor-xi-inhibitor-provide-anticoagulation-effectiveness-doacs-af-improving-safety-nejm-jw.NA58360

[7] NEJM. Abelacimab, a novel factor XI/XIa inhibitor, vs rivaroxaban in patients with atrial fibrillation: primary results of the AZALEA-TIMI 71 randomized trial. URL: https://www.nejm.org/doi/full/10.1056/NEJMoa2407105

FAQ

Q: What is abelacimab approved for?

A: Abelacimab is under investigation for the prevention of stroke in patients with atrial fibrillation. The AZALEA-TIMI 71 trial evaluated its efficacy compared to rivaroxaban, showing a 30% reduction in stroke risk. The drug is not yet FDA approved but shows promise for patients at moderate-to-high stroke risk [1].

Q: How does abelacimab work?

A: Abelacimab is a monoclonal antibody that inhibits factor XI, which plays a role in the coagulation cascade. By targeting factor XI, abelacimab aims to reduce thrombus formation while minimizing bleeding risks associated with traditional anticoagulants like rivaroxaban [1].

Q: What is the recommended dose of abelacimab?

A: Abelacimab is administered as a monthly subcutaneous injection at a dose of 90 mg. Clinicians should consult current prescribing information for full dosing guidance. Full dosing guidance is available in the prescribing information for abelacimab. Clinicians should consult the current label before prescribing [6].

Q: What are the most common side effects of abelacimab?

A: Common side effects of abelacimab include immune-mediated adverse reactions such as pneumonitis and colitis. Discontinuation rates due to adverse events are not available in public source summaries. The complete adverse event profile is available in the prescribing information [1].

Abelacimab Reduces Stroke Risk: AZALEA-TIMI 71 Trial Shows Improved Safety Profile in Atrial Fibrillation

Abelacimab Reduces Stroke Risk: AZALEA-TIMI 71 Trial Shows Improved Safety Profile in Atrial Fibrillation

Clinical Perspective

Clinical Context

Key Findings

Safety & Tolerability

What This Means for Clinical Practice

Study Design

References

FAQ

References

Get weekly clinical updates for Cardiology in your inbox.

Related Clinical Updates

FDA Approves Baxdrostat for Resistant Hypertension: 10 mmHg SBP Reduction in BaxHTN Trial

FDA Approves Empagliflozin for HFpEF: 21% Heart Failure Hospitalization Reduction in EMPEROR-Preserved Trial

FDA Approves Semaglutide for HFpEF: 13.3% KCCQ Score Improvement in STEP-HFpEF Trial

Verified HCP Portal